Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Quintessence Biosciences Presents Human Ribonuclease Variant, QBI-139, at the American Society of Clinical Oncology Meeting

Abstract:
Quintessence today announced that data for their lead EVade™ Ribonuclease, called QBI-139, will be presented at the American Society of Clinical Oncology 46th Annual Meeting.

Quintessence Biosciences Presents Human Ribonuclease Variant, QBI-139, at the American Society of Clinical Oncology Meeting

Madison, WI | Posted on June 7th, 2010

QBI-139 is a protein therapeutic that targets the RNA in cancer cells. The data from abstract TPS162 will be presented at 8 AM on Monday June 7, 2010. The focus will be on the design of the Phase I clinical trial of QBI-139. QBI-139 has shown broad single agent activity against a variety of cancer models addressing significant unmet need, such as non-small cell lung and pancreatic cancers.

####

About Quintessence Biosciences
Quintessence Biosciences, Inc. is a private biopharmaceutical company focused on development of cancer therapies based on the proprietary EVade™ Ribonuclease technology. Quintessence’s first product candidate, QBI- 139, is in a Phase 1 clinical trial at The University of Texas M.D. Anderson Cancer Center and The University of Wisconsin Carbone Cancer Center. The company also has a pipeline of other EVade™ Ribonuclease products in preclinical research. For more information, visit www.quintbio.com.

About the American Society of Clinical Oncology
The 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) is being held in Chicago, June 4-8, 2010. This year's Annual Meeting will focus on Advancing Quality through Innovation. More than 30,000 cancer specialists from around the world will gather to discuss the latest innovations in research, quality, practice and technology in cancer. For more information, visit chicago2010.asco.org/Home.aspx

About the ASCO Annual Meeting Trials in Progress Poster Session
The objective of the Trials in Progress Poster Session is to publicize ongoing phase I or phase II trials and stimulate discussion and participation among peers. The posters discuss the science behind the trial, including pre-clinical data. In addition, the posters will describe the trial design and current enrollment status.

For more information, please click here

Contacts:
Dr. Laura Strong
President and Chief Operating Officer
608-441-2950


Copyright © Quintessence Biosciences

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

ICN2 researchers compute unprecedented values for spin lifetime anisotropy in graphene November 17th, 2017

Math gets real in strong, lightweight structures: Rice University researchers use 3-D printers to turn century-old theory into complex schwarzites November 16th, 2017

The stacked color sensor: True colors meet minimization November 16th, 2017

Nanometrics to Participate in the 6th Annual NYC Investor Summit 2017 November 16th, 2017

Nanomedicine

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3’s significant potential role in Immuno-Oncology at SITC Annual Meeting November 14th, 2017

Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference November 14th, 2017

A new way to mix oil and water: Condensation-based method developed at MIT could create stable nanoscale emulsions November 8th, 2017

Nanoshells could deliver more chemo with fewer side effects: In vitro study verifies method for remotely triggering release of cancer drugs November 8th, 2017

Announcements

ICN2 researchers compute unprecedented values for spin lifetime anisotropy in graphene November 17th, 2017

Math gets real in strong, lightweight structures: Rice University researchers use 3-D printers to turn century-old theory into complex schwarzites November 16th, 2017

The stacked color sensor: True colors meet minimization November 16th, 2017

Nanometrics to Participate in the 6th Annual NYC Investor Summit 2017 November 16th, 2017

Events/Classes

Nanometrics to Participate in the 6th Annual NYC Investor Summit 2017 November 16th, 2017

Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference November 14th, 2017

Leti Will Present 11 Papers and Host More-than-Moore Technologies Workshop November 14th, 2017

TUBALL nanotube-based concentrates recognised as the most innovative raw material for composites by JEC Group November 7th, 2017

Nanobiotechnology

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3’s significant potential role in Immuno-Oncology at SITC Annual Meeting November 14th, 2017

Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference November 14th, 2017

Nanoshells could deliver more chemo with fewer side effects: In vitro study verifies method for remotely triggering release of cancer drugs November 8th, 2017

Age-old malaria treatment found to improve nanoparticle delivery to tumors: Nanomedicine researchers find new use for 70-year-old drug November 7th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project